Consequently, in the presence of catecholamine overproduction, erlotinib may impede myocardial protective signaling by inhibiting EGFR, ultimately leading to HF (Noma et al., 2007; Nagashio et al., 2021). The gene discussed is EGFR; the disease is hydrops fetalis.